Literature DB >> 6539491

Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions.

O Vesterqvist, K Gréen.   

Abstract

Quantitation of 2,3-dinor-thromboxane B2 (2,3-dinor-TxB2) was performed by gas chromatography-mass spectrometry. Under normal conditions the urinary excretion of 2,3-dinor-TxB2 was relatively constant in the same individual from day to day but during a 24-hour period a somewhat higher excretion rate was found during the first few hours after awakening. A pronounced reduction of the urinary excretion of 2,3-dinor-TxB2 was found after oral administration of 500 mg of aspirin or 50 mg of indomethacin, while 500 mg of paracetamol did not affect the urinary excretion. Increased excretion of 2,3-dinor-TxB2 was found in normal pregnancies and in diseases such as diabetes mellitus and homocysteinuria in comparison to the urinary excretion in normal healthy subjects. We also report one case, where the urinary excretion of 2,3-dinor-TxB2 was increased for a short period following the first symptoms of a myocardial infarction and those data indicate that thromboxane A2 (TxA2) may be of pathophysiological importance in human myocardial infarction. The results strongly indicate that measurements of the urinary excretion of 2,3-dinor-TxB2 should be meaningful as a tool for investigation of the involvement of thromboxane in various pathophysiological processes in vivo in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6539491     DOI: 10.1016/0090-6980(84)90098-4

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  10 in total

1.  Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man.

Authors:  H Bippi; J C Frölich
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

2.  Rapid recovery of in vivo prostacyclin formation after inhibition by aspirin. Evidence from measurements of the major urinary metabolite of prostacyclin by GC-MS.

Authors:  O Vesterqvist
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Functional role of thromboxane production by acutely rejecting renal allografts in rats.

Authors:  T M Coffman; W E Yarger; P E Klotman
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

4.  Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man.

Authors:  O Vesterqvist; K Gréen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction.

Authors:  P Henriksson; A Wennmalm; O Edhag; O Vesterqvist; K Green
Journal:  Br Heart J       Date:  1986-06

6.  Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.

Authors:  G Di Minno; G Davì; M Margaglione; F Cirillo; E Grandone; G Ciabattoni; I Catalano; P Strisciuglio; G Andria; C Patrono
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 7.  Influences of lipid-modifying agents on hemostasis.

Authors:  C R Sirtori; S Colli
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

8.  Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis.

Authors:  David S Wald; Joan K Morris; Nicholas J Wald
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

9.  Aspirin: pharmacology and clinical applications.

Authors:  Enma V Paez Espinosa; John P Murad; Fadi T Khasawneh
Journal:  Thrombosis       Date:  2011-11-17

10.  Effects of paracetamol on NOS, COX, and CYP activity and on oxidative stress in healthy male subjects, rat hepatocytes, and recombinant NOS.

Authors:  Arne Trettin; Anke Böhmer; Maria-Theresia Suchy; Irmelin Probst; Ulrich Staerk; Dirk O Stichtenoth; Jürgen C Frölich; Dimitrios Tsikas
Journal:  Oxid Med Cell Longev       Date:  2014-03-31       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.